AZN vs. ELAN: AstraZeneca vs. Elanco Animal Health Stock Comparison
How do AstraZeneca (AZN) and Elanco Animal Health (ELAN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
AstraZeneca (AZN) and Elanco Animal Health (ELAN) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
Elanco Animal Health (ELAN) trades as ordinary local shares, while AstraZeneca (AZN) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | AZN | ELAN |
|---|---|---|
| Name | AstraZeneca PLC American Depositary Shares | Elanco Animal Health Incorporated |
| Country/Region | United Kingdom | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 289.14 billion USD | 12.86 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | May 12, 1993 | September 20, 2018 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AZN | ELAN |
|---|---|---|
| Total Return (1Y) | 12.64% | 24.03% |
| Total Return (3Y, Annualized) | 15.75% | 37.47% |
| Total Return (5Y, Annualized) | 10.63% | -4.24% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Elanco Animal Health (ELAN) has an aggressive beta of 1.65, indicating higher sensitivity to broad-market moves, while AstraZeneca (AZN) is defensive at 0.22 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.
| Metric | AZN | ELAN |
|---|---|---|
| Volatility (1Y, Annualized) | 28.21% | 43.57% |
| Beta (5Y) | 0.22 | 1.65 |
| Max Drawdown (5Y) | -27.87% | -75.59% |
| Avg. Volume (3M) | 3.14M | 5.65M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AZN | ELAN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.30 | 0.45 |
| Sortino Ratio (1Y) | 0.44 | 0.66 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: AstraZeneca (AZN) earns 22.57% on shareholders’ equity, ranked against its industry; Elanco Animal Health (ELAN) has no ROE this period.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.57%
- Max
- 109.18%
- AZN
- 22.57%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ELAN
- --
Net Margin (TTM)
Elanco Animal Health (ELAN) reports a negative net margin of -2.86%, usually indicating a net loss over the period. Meanwhile AstraZeneca (AZN) reports 17.68%, ranking against industry peers normally.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.68%
- Max
- 18.05%
- AZN
- 17.68%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-2.86%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- ELAN
- -2.86%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
AstraZeneca (AZN) at 29.57% operates in the top operating margin quartile, ahead of Elanco Animal Health (ELAN) at 6.64%, which runs around its industry’s norm.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
29.57%
- Max
- 83.12%
- AZN
- 29.57%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.64%
- Max
- 83.12%
- Q3
- 14.77%
- ELAN
- 6.64%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AZN | ELAN |
|---|---|---|
| ROE (TTM) | 22.57% | -- |
| ROA (TTM) | 8.59% | -- |
| Net Margin (TTM) | 17.68% | -2.86% |
| Operating Margin (TTM) | 29.57% | 6.64% |
| Gross Margin (TTM) | 81.78% | 56.18% |
Growth
Revenue Growth
Both AstraZeneca (AZN) at 8.63% and Elanco Animal Health (ELAN) at 6.22% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
AstraZeneca (AZN) at 45.33% is around its peer norm for EPS growth, while Elanco Animal Health (ELAN) at -169.12% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | AZN | ELAN |
|---|---|---|
| Revenue Growth (YoY) | 8.63% | 6.22% |
| Revenue Growth (3Y CAGR) | 9.82% | 2.25% |
| EPS Growth (YoY) | 45.33% | -169.12% |
| EPS Growth (3Y CAGR) | 45.80% | -- |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: AstraZeneca (AZN) shows current ratio of 1.01 against its industry benchmark, while Elanco Animal Health (ELAN) has no reading this period.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.01
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AZN
- 1.01
- Min
- 0.10
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- ELAN
- --
Debt / Equity (MRQ)
Elanco Animal Health (ELAN) at 0.64 carries an industry-typical debt-to-equity mix, while AstraZeneca (AZN) at 0.66 uses more debt funding than most peers.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.66
- Max
- 1.42
- AZN
- 0.66
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.64
- Max
- 1.42
- Q3
- 0.65
- ELAN
- 0.64
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AZN | ELAN |
|---|---|---|
| Current Ratio (MRQ) | 1.01 | -- |
| Debt / Equity (MRQ) | 0.66 | 0.64 |
| Net Debt / EBITDA | 1.23 | 3.49 |
Dividends
Dividend Yield (TTM)
Elanco Animal Health (ELAN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a yield of 1.73%, ranking against industry peers normally.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73%
- AZN
- 1.73%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Elanco Animal Health (ELAN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a payout of 45.38%, ranking against industry peers normally.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.38%
- AZN
- 45.38%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AZN | ELAN |
|---|---|---|
| Dividend Yield (TTM) | 1.73% | 0.00% |
| Dividend Payout Ratio (TTM) | 45.38% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: AstraZeneca (AZN) trades at 26.37 times trailing earnings, ranked against its peers, while Elanco Animal Health (ELAN) has no P/E ratio this period.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.37
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- AZN
- 26.37
- Q1
- 13.30
- Min
- 0.07
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- ELAN
- --
P/S Ratio (TTM)
Elanco Animal Health (ELAN) at 2.50 sits in the cheaper P/S ratio quartile while AstraZeneca (AZN) at 4.63 prices around its industry’s middle — ELAN costs less per dollar of sales, though read it alongside growth and margins.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.63
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- AZN
- 4.63
- Q1
- 3.01
- Min
- 0.01
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.50
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- ELAN
- 2.50
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both AstraZeneca (AZN) at 5.59 and Elanco Animal Health (ELAN) at 1.95 are valued close to their industries’ norm against book — neither stands out from peers.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.59
- Max
- 13.53
- Q3
- 6.54
- AZN
- 5.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.95
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- ELAN
- 1.95
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AZN | ELAN |
|---|---|---|
| P/E Ratio (TTM) | 26.37 | -- |
| P/S Ratio (TTM) | 4.63 | 2.50 |
| P/B Ratio (MRQ) | 5.59 | 1.95 |
| Free Cash Flow Yield (TTM) | 1.95% | -- |